Galapagos NV (GXEA) - Net Assets
Based on the latest financial reports, Galapagos NV (GXEA) has net assets worth €3.25 Billion EUR (≈ $3.80 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.37 Billion ≈ $3.94 Billion USD) and total liabilities (€119.06 Million ≈ $139.19 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GXEA goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.25 Billion |
| % of Total Assets | 96.47% |
| Annual Growth Rate | 17.49% |
| 5-Year Change | 22.41% |
| 10-Year Change | N/A |
| Growth Volatility | 42.12 |
Galapagos NV - Net Assets Trend (2016–2025)
This chart illustrates how Galapagos NV's net assets have evolved over time, based on quarterly financial data. See Galapagos NV liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Galapagos NV (2016–2025)
The table below shows the annual net assets of Galapagos NV from 2016 to 2025. For live valuation and market cap data, see GXEA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €3.24 Billion ≈ $3.78 Billion |
+11.70% |
| 2024-12-31 | €2.90 Billion ≈ $3.39 Billion |
+3.63% |
| 2023-12-31 | €2.80 Billion ≈ $3.27 Billion |
+10.67% |
| 2022-12-31 | €2.53 Billion ≈ $2.95 Billion |
-4.44% |
| 2021-12-31 | €2.64 Billion ≈ $3.09 Billion |
-1.01% |
| 2020-12-31 | €2.67 Billion ≈ $3.12 Billion |
-7.14% |
| 2019-12-31 | €2.88 Billion ≈ $3.36 Billion |
+136.83% |
| 2018-12-31 | €1.21 Billion ≈ $1.42 Billion |
+19.99% |
| 2017-12-31 | €1.01 Billion ≈ $1.18 Billion |
+33.38% |
| 2016-12-31 | €758.70 Million ≈ $887.00 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Galapagos NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 32284900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €210.58 Million | 6.51% |
| Other Components | €3.03 Billion | 93.49% |
| Total Equity | €3.24 Billion | 100.00% |
Galapagos NV Competitors by Market Cap
The table below lists competitors of Galapagos NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stagwell Inc
NASDAQ:STGW
|
$1.60 Billion |
|
Spartan Delta Corp
TO:SDE
|
$1.60 Billion |
|
FirstSun Capital Bancorp Common Stock
NASDAQ:FSUN
|
$1.60 Billion |
|
Akzo Nobel India Limited
NSE:AKZOINDIA
|
$1.60 Billion |
|
City Union Bank Limited
NSE:CUB
|
$1.59 Billion |
|
Icade SA
PA:ICAD
|
$1.59 Billion |
|
Alembic Pharmaceuticals Limited
NSE:APLLTD
|
$1.59 Billion |
|
GS Engineering & Construction
KO:006360
|
$1.59 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Galapagos NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,896,939,000 to 3,235,868,000, a change of 338,929,000 (11.7%).
- Net income of 320,884,000 contributed positively to equity growth.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €320.88 Million | +9.92% |
| Other Changes | €18.05 Million | +0.56% |
| Total Change | €- | 11.70% |
Book Value vs Market Value Analysis
This analysis compares Galapagos NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.24x to 0.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €19.87 | €24.60 | x |
| 2018-12-31 | €22.29 | €24.60 | x |
| 2019-12-31 | €44.47 | €24.60 | x |
| 2020-12-31 | €40.82 | €24.60 | x |
| 2021-12-31 | €40.32 | €24.60 | x |
| 2022-12-31 | €38.37 | €24.60 | x |
| 2023-12-31 | €42.42 | €24.60 | x |
| 2024-12-31 | €43.96 | €24.60 | x |
| 2025-12-31 | €49.10 | €24.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Galapagos NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.92%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.85%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.05x
- Recent ROE (9.92%) is above the historical average (-0.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 7.12% | 41.70% | 0.12x | 1.43x | €-21.86 Million |
| 2017 | -11.43% | -91.04% | 0.10x | 1.27x | €-216.90 Million |
| 2018 | -2.41% | -10.13% | 0.20x | 1.19x | €-150.68 Million |
| 2019 | 5.21% | 17.73% | 0.14x | 2.11x | €-137.72 Million |
| 2020 | -11.44% | -63.89% | 0.08x | 2.14x | €-572.47 Million |
| 2021 | -3.91% | -21.29% | 0.09x | 1.96x | €-367.57 Million |
| 2022 | -8.63% | -43.14% | 0.11x | 1.87x | €-470.59 Million |
| 2023 | 7.57% | 88.31% | 0.06x | 1.56x | €-67.86 Million |
| 2024 | 2.56% | 26.88% | 0.07x | 1.43x | €-215.61 Million |
| 2025 | 9.92% | 28.85% | 0.33x | 1.05x | €-2.70 Million |
Industry Comparison
This section compares Galapagos NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,435,678,106
- Average return on equity (ROE) among peers: -30.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Galapagos NV (GXEA) | €3.25 Billion | 7.12% | 0.04x | $1.60 Billion |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $179.82 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.05 Billion | -15.51% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.10 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.60 Million | -113.13% | 0.23x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $20.05 Billion |
About Galapagos NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more